Truist lowered the firm’s price target on Viridian Therapeutics (VRDN) to $36 from $40 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 earnings in Biotech.

Truist lowered the firm’s price target on BeOne Medicines (ONC) to $411 from $412 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 earnings in Biotech. Reactivity ...

I initiate coverage on Forte Biosciences stock at a 'Hold' rating due to both pipeline risk and upcoming clinical catalysts.

Profusa (PFSA) shares jumped 173% following announcement of $30M equity deal to acquire PanOmics diagnostics platform from BioInsights LLC.

Eli Lilly has won FDA approval for its oral obesity drug Foundayo™ (orforglipron), but the stock bounce was short lived as ...

Cannara Biotech Inc. ('Cannara”, 'the Company”, 'us” or 'we”) (TSX: LOVE) (OTCQX: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis products at affordable prices with two ...

Biotechnology-driven Future Society has collected microbes from cloud environments, sequenced them and analysed the scent ...

Analysts say the Tubulis platform technologies that yielded these ADCs could also help Gilead develop drugs in other ...

Shares slightly lower as oil resumes gains after Iran shuts Strait of Hormuz; Bendigo Bank to cut jobs; Orora downgrades earnings, pauses buyback. Follow live.

Using proprietary real-world patient data and an early validated drug candidate, Analgesia.ai is building an AI-powered ...

For the past 7 years, pharmaceuticals that work as glucagon-like peptide 1 (GLP-1) receptor agonists have dominated the weight-loss and diabetes markets. These drugs, currently so ...

In the current geopolitical and capital-market uncertainty, biotechs that have not mastered the basics are the ones ...